Oxford BioDynamics (GB:OBD) has released an update.
Oxford BioDynamics has partnered with Goodbody Clinic to widen the availability of its EpiSwitch Prostate Screening Test, a blood test that significantly improves prostate cancer detection accuracy, across the UK through Goodbody’s extensive clinic network and home visit service. The innovative test, which offers a predictive accuracy leap from 55% to 94%, is now accessible for men to order online for clinic appointments or home-based sample collection. This collaboration aims to enhance the standard of care by leveraging Goodbody Clinic’s reach and the advanced EpiSwitch technology.
For further insights into GB:OBD stock, check out TipRanks’ Stock Analysis page.
